Gynecological Cancers
Conditions
Brief summary
This is an open-label, first-in-human, dose escalation study evaluating investigational drug PORPHYSOSMES (PS, pegylated porphyrin-lipid conjugate-containing nanoparticle suspension) and 64Cu-PORPHYSOMES (64Cu-PS, pegylated Copper-64 labelled porphyrin-lipid conjugate-containing nanoparticle suspension) for PET/CT imaging assessments in patients with metastatic/advanced gynecological tumors.
Interventions
DRUGPORPHYSOMES
Pegylated porphyrin-lipid conjugate-containing nanoparticle suspension
DRUG64Cu-PORPHYSOMES
Pegylated Copper-64 labelled porphyrin-lipid conjugate-containing nanoparticle suspension
Sponsors
University Health Network, Toronto
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Female patients age ≥ 18 years. * Life expectancy of \>3 months. * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2. * Histologically confirmed metastatic advanced gynecological cancer. All epithelial subtypes are permitted. Patients receiving standard of care oncological treatment (i.e. chemotherapy and/or radiation) will be included. * Patient is able to understand and is willing to sign a written informed consent document prior to registration/enrollment on to study. * Patient is willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures. * Patients of childbearing potential (as assessed by their local Investigator) and their partners who are sexually active must agree to the use of 2 highly effective forms of contraception throughout the period of study treatment and for 12 months after last dose of study drug. * Baseline corrected QT (QTc) interval prolongation \< 470 milliseconds. * Within 8 days of the proposed enrollment patients must have adequate organ function.
Exclusion criteria
* Patient is a candidate for therapy with curative intent. * Patient has a contraindication to PET/CT imaging, including, but not limited to, phobias associated with imaging (e.g. claustrophobia) and those who cannot lie still in the supine position for at least 20 minutes. * Patients receiving nuclear medicine scans with other radiopharmaceutical agents (ex: 18F-FDG or other) during the study's exclusionary period will be excluded from the study. * Patients with known myelodysplastic syndrome/acute myeloid leukemia. * Treatment with an investigational drug within 15 days prior to study registration. * Patients must not receive any other oncological treatments, including chemotherapy and/or radiation, within 2 weeks before starting study drug administration (and for 28 days after study drug administration). * History of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in study. * Patients with a known active COVID-19 infection at the time of registration/enrollment. * Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the Investigator would make the subject inappropriate for entry into this study. * Uncontrolled inter-current illness including, but not limited to, ongoing or active infection requiring IV antibiotics, symptomatic congestive heart failure, unstable angina pectoris, unstable cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Pregnant or breast-feeding women. * Unresolved toxicity \> CTCAE grade 1 from previous anti-cancer therapies, including radiotherapy, with exception. * Retinopathy ≥ grade 2. * Patients with porphyria. * Patients that have undergone a splenectomy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Dose Limiting Toxicities (DLTs) | 1 year | To determine the recommended dose of PORPHYSOME. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of AEs | 1 year | To evaluate the safety and tolerability of PS administration in subjects with advanced metastatic gynaecological cancers. |
| Tissue distribution and tumour uptake kinetics | 1 year | To identify the tissue distribution and tumour uptake of escalating PS drug doses. |
| Concentration-time curves | 1 year | To identify the plasma pharmacokinetic profiles of escalating PS drug doses. |
| Image- and model-based organ dosimetry | 1 year | To estimate the radiation dosimetry of 64Cu-PS in healthy organ structures. |
Countries
Canada
Contacts
Primary ContactStephanie Lheureux, MD
Outcome results
None listed